Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

22.39 -0.09 (-0.42%)
Streaming Delayed Price Updated: 11:59 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 344,731
Open 22.47
Bid (Size) 22.37 (2)
Ask (Size) 22.40 (2)
Prev. Close 22.48
Today's Range 22.00 - 22.73
52wk Range 20.84 - 34.27
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-7.35%
-7.35%
1 Month
-9.23%
-9.23%
3 Month
-2.12%
-2.12%
6 Month
-18.63%
-18.63%
1 Year
+0.61%
+0.61%

More News

Read More
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
Via Chartmill
Recap: Corcept Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
Earnings Preview: Corcept Therapeutics
Via Benzinga
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Despite its growth, NASDAQ:CORT remains within the realm of affordability.
Via Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
Via Chartmill
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday?
Via Benzinga
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
Via Chartmill
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
Via Chartmill
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Crude Oil Down 2%; Tesla Deliveries Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.